In this week’s video, Dr. Durie discusses the two main types of minimal residual disease (MRD) tests for multiple myeloma – next-generation sequencing (NGS) and next-generation flow (NGF).

BOTTOM LINE:
The FDA approval of the NGS test for MRD is excellent news, but this testing is still not ready for use in day-to-day clinical practice.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
The Impact of Nutrition on Side Effect Management
Next Post
What are bispecific antibodies?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.